Efficacy of probing the nasolacrimal duct with adjunctive mitomycin-C for epiphora in adults

Chieh Chih Tsai, Hui Chuan Kau, Shu Ching Kao, Wen-Ming Hsu, Jorn H. Liu

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: To investigate the efficacy and safety of adjunctive low-dose mitomycin-C during lacrimal probing for adults with blocked nasolacrimal ducts. Design: Prospective, noncomparative, interventional case series. Participants: From January 1998 to December 2000, a total of 32 adult patients (36 eyes) seen with epiphora caused by primary nasolacrimal duct obstruction was treated and evaluated. Intervention: Lacrimal probing with adjunctive mitomycin-C (0.2 mg/ml). Main Outcome Measures: Objective evaluation of patency with irrigation, as well as patients' subjective assessment of improvement. Results: For 32 of the treated eyes (89%), the nasolacrimal duct remained open 9 months after treatment. Repeat procedure was successful for two of the remaining four eyes with recurrent obstruction during follow-up, yielding an overall patency rate of 94%. Patient satisfaction was assessed after 9 months and indicated that the epiphora was at least mildly improved for 30 (83%) of the treated eyes. Watering was completely absent for nine eyes (25%), rated as moderately improved for 17 (47%), and mildly improved for 4 (11%). No complications were encountered over the 9-month follow-up period. Conclusions: Our experience suggests good long-term results for probing with adjunctive, topical Mitomycin-C for cases of adult epiphora caused by obstruction of the nasolacrimal duct followed by repeat procedure if necessary. It can be recommended as a simple, effective, and minimally invasive technique, with no significant complications resulting from low-dose use in our study.

Original languageEnglish
Pages (from-to)172-174
Number of pages3
JournalOphthalmology
Volume109
Issue number1
DOIs
Publication statusPublished - Jan 12 2002
Externally publishedYes

Fingerprint

Nasolacrimal Duct
Lacrimal Apparatus Diseases
Mitomycin
Tears
Patient Satisfaction
Outcome Assessment (Health Care)
Safety

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Efficacy of probing the nasolacrimal duct with adjunctive mitomycin-C for epiphora in adults. / Tsai, Chieh Chih; Kau, Hui Chuan; Kao, Shu Ching; Hsu, Wen-Ming; Liu, Jorn H.

In: Ophthalmology, Vol. 109, No. 1, 12.01.2002, p. 172-174.

Research output: Contribution to journalArticle

Tsai, Chieh Chih ; Kau, Hui Chuan ; Kao, Shu Ching ; Hsu, Wen-Ming ; Liu, Jorn H. / Efficacy of probing the nasolacrimal duct with adjunctive mitomycin-C for epiphora in adults. In: Ophthalmology. 2002 ; Vol. 109, No. 1. pp. 172-174.
@article{83eb0c95888e440eae9f5098988eac3c,
title = "Efficacy of probing the nasolacrimal duct with adjunctive mitomycin-C for epiphora in adults",
abstract = "Purpose: To investigate the efficacy and safety of adjunctive low-dose mitomycin-C during lacrimal probing for adults with blocked nasolacrimal ducts. Design: Prospective, noncomparative, interventional case series. Participants: From January 1998 to December 2000, a total of 32 adult patients (36 eyes) seen with epiphora caused by primary nasolacrimal duct obstruction was treated and evaluated. Intervention: Lacrimal probing with adjunctive mitomycin-C (0.2 mg/ml). Main Outcome Measures: Objective evaluation of patency with irrigation, as well as patients' subjective assessment of improvement. Results: For 32 of the treated eyes (89{\%}), the nasolacrimal duct remained open 9 months after treatment. Repeat procedure was successful for two of the remaining four eyes with recurrent obstruction during follow-up, yielding an overall patency rate of 94{\%}. Patient satisfaction was assessed after 9 months and indicated that the epiphora was at least mildly improved for 30 (83{\%}) of the treated eyes. Watering was completely absent for nine eyes (25{\%}), rated as moderately improved for 17 (47{\%}), and mildly improved for 4 (11{\%}). No complications were encountered over the 9-month follow-up period. Conclusions: Our experience suggests good long-term results for probing with adjunctive, topical Mitomycin-C for cases of adult epiphora caused by obstruction of the nasolacrimal duct followed by repeat procedure if necessary. It can be recommended as a simple, effective, and minimally invasive technique, with no significant complications resulting from low-dose use in our study.",
author = "Tsai, {Chieh Chih} and Kau, {Hui Chuan} and Kao, {Shu Ching} and Wen-Ming Hsu and Liu, {Jorn H.}",
year = "2002",
month = "1",
day = "12",
doi = "10.1016/S0161-6420(01)00855-7",
language = "English",
volume = "109",
pages = "172--174",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Efficacy of probing the nasolacrimal duct with adjunctive mitomycin-C for epiphora in adults

AU - Tsai, Chieh Chih

AU - Kau, Hui Chuan

AU - Kao, Shu Ching

AU - Hsu, Wen-Ming

AU - Liu, Jorn H.

PY - 2002/1/12

Y1 - 2002/1/12

N2 - Purpose: To investigate the efficacy and safety of adjunctive low-dose mitomycin-C during lacrimal probing for adults with blocked nasolacrimal ducts. Design: Prospective, noncomparative, interventional case series. Participants: From January 1998 to December 2000, a total of 32 adult patients (36 eyes) seen with epiphora caused by primary nasolacrimal duct obstruction was treated and evaluated. Intervention: Lacrimal probing with adjunctive mitomycin-C (0.2 mg/ml). Main Outcome Measures: Objective evaluation of patency with irrigation, as well as patients' subjective assessment of improvement. Results: For 32 of the treated eyes (89%), the nasolacrimal duct remained open 9 months after treatment. Repeat procedure was successful for two of the remaining four eyes with recurrent obstruction during follow-up, yielding an overall patency rate of 94%. Patient satisfaction was assessed after 9 months and indicated that the epiphora was at least mildly improved for 30 (83%) of the treated eyes. Watering was completely absent for nine eyes (25%), rated as moderately improved for 17 (47%), and mildly improved for 4 (11%). No complications were encountered over the 9-month follow-up period. Conclusions: Our experience suggests good long-term results for probing with adjunctive, topical Mitomycin-C for cases of adult epiphora caused by obstruction of the nasolacrimal duct followed by repeat procedure if necessary. It can be recommended as a simple, effective, and minimally invasive technique, with no significant complications resulting from low-dose use in our study.

AB - Purpose: To investigate the efficacy and safety of adjunctive low-dose mitomycin-C during lacrimal probing for adults with blocked nasolacrimal ducts. Design: Prospective, noncomparative, interventional case series. Participants: From January 1998 to December 2000, a total of 32 adult patients (36 eyes) seen with epiphora caused by primary nasolacrimal duct obstruction was treated and evaluated. Intervention: Lacrimal probing with adjunctive mitomycin-C (0.2 mg/ml). Main Outcome Measures: Objective evaluation of patency with irrigation, as well as patients' subjective assessment of improvement. Results: For 32 of the treated eyes (89%), the nasolacrimal duct remained open 9 months after treatment. Repeat procedure was successful for two of the remaining four eyes with recurrent obstruction during follow-up, yielding an overall patency rate of 94%. Patient satisfaction was assessed after 9 months and indicated that the epiphora was at least mildly improved for 30 (83%) of the treated eyes. Watering was completely absent for nine eyes (25%), rated as moderately improved for 17 (47%), and mildly improved for 4 (11%). No complications were encountered over the 9-month follow-up period. Conclusions: Our experience suggests good long-term results for probing with adjunctive, topical Mitomycin-C for cases of adult epiphora caused by obstruction of the nasolacrimal duct followed by repeat procedure if necessary. It can be recommended as a simple, effective, and minimally invasive technique, with no significant complications resulting from low-dose use in our study.

UR - http://www.scopus.com/inward/record.url?scp=0036135721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036135721&partnerID=8YFLogxK

U2 - 10.1016/S0161-6420(01)00855-7

DO - 10.1016/S0161-6420(01)00855-7

M3 - Article

VL - 109

SP - 172

EP - 174

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 1

ER -